ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
Source: BioPharma Dive - Latest News
At a big meeting for cardiovascular medicines, Cytokinetics and Arrowhead aimed to separate their drugs from competitors while a failed study pressured Alnylam.